0001415889-24-008155.txt : 20240315
0001415889-24-008155.hdr.sgml : 20240315
20240315192341
ACCESSION NUMBER: 0001415889-24-008155
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240314
FILED AS OF DATE: 20240315
DATE AS OF CHANGE: 20240315
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Booth Bruce
CENTRAL INDEX KEY: 0001451612
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39460
FILM NUMBER: 24756498
MAIL ADDRESS:
STREET 1: 890 WINTER STREET
STREET 2: SUITE 320
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kymera Therapeutics, Inc.
CENTRAL INDEX KEY: 0001815442
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 812992166
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 NORTH BEACON STREET, 4TH FLOOR
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 857-285-5314
MAIL ADDRESS:
STREET 1: 500 NORTH BEACON STREET, 4TH FLOOR
CITY: WATERTOWN
STATE: MA
ZIP: 02472
4
1
form4-03152024_110334.xml
X0508
4
2024-03-14
0001815442
Kymera Therapeutics, Inc.
KYMR
0001451612
Booth Bruce
C/O KYMERA THERAPEUTICS, INC.
200 ARSENAL YARDS BLVD., SUITE 230
WATERTOWN
MA
02472
true
false
false
false
1
Common Stock
2024-03-14
4
S
0
34473
39.73
D
4641602
I
See footnote
Common Stock
2024-03-14
4
S
0
10846
40.66
D
4630756
I
See footnote
Common Stock
2024-03-14
4
S
0
781
41.51
D
4629975
I
See footnote
Common Stock
2024-03-14
4
S
0
7292
39.73
D
821538
I
See footnote
Common Stock
2024-03-14
4
S
0
2233
40.66
D
819305
I
See footnote
Common stock
2024-03-14
4
S
0
154
41.51
D
819151
I
See footnote
Common Stock
2024-03-15
4
S
0
8126
39.31
D
4621849
I
See footnote
Common Stock
2024-03-15
4
S
0
49591
40.62
D
4572258
I
See footnote
Common Stock
2024-03-15
4
S
0
1593
41.23
D
4570665
I
See footnote
Common Stock
2024-03-15
4
S
0
1714
39.31
D
817437
I
See footnote
Common Stock
2024-03-15
4
S
0
10411
40.62
D
807026
I
See footnote
Common Stock
2024-03-15
4
S
0
329
41.23
D
806697
I
See footnote
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.2558 to $40.2537 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (8), (9) and (10).
These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of his pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.26 to $41.2563 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.2712 to $41.7267 inclusive.
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024.
The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.13 to $40.1296 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.1375 to $41.13 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.1413 to $41.43 inclusive.
/s/ Ommer Chohan, Attorney-in-Fact
2024-03-15